Biological fingerprint identifies leiomyomatosis and renal cell cancer
A diagnostic test involves screening tumor samples for a particular molecular fingerprint unique to leiomyomatosis and renal cell cancer (HLRCC). A protein modification induced by FH deficiency (due to an over-abundance of fumarate) was identified by scientists at the Henry Wellcome Building for Molecular Physiology, University of Oxford (United Kingdom).
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063